ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 568

Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals

Laura Hunt1, Sahar Musaad1,2, John Stephenson3, Becki Burn2, Isao Matsuura1, Kulveer Mankia1, Jackie L. Nam1 and Paul Emery1, 1NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Microbiology, Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom, 3Department Health Sciences, University of Huddersfield, Huddersfield, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: ACPA, biomarkers and rheumatoid arthritis, pathogenesis

Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Whilst the exact aetiology of rheumatoid arthritis (RA) remains unclear, current concepts suggest an environmental link with possible microbial triggers.  Studying individuals at-risk of RA allows a unique opportunity to explore possible relationships.  Furthermore, the identification of predictors of progression from at-risk to RA is of great clinical utility.   Triggering receptor expressed on myeloid cells (TREM) modulates the innate immune response by either amplifying or dampening the toll like receptors (TLR) induced signalling1.  Given the upstream nature of soluble-TREM (sTREM), and its close proximity to TLR in innate immune response to microbial triggers, we hypothesis that sTREM could be one of the first indicators of progression to RA.   

Methods: sTREM was measured using Human TREM-1 Quantikine ELISA (R&D Systems, Minneapolis) in 32 at-risk individuals; 16 of whom progressed (ACPA+ Prog) and 16 whom did not (ACPA+ NProg), and 16 early RA (ERA) patients.  The ACPA+ cohort had no evidence of ultrasound synovitis at baseline. Binary logistic regression models were conducted on at-risk patients. Model discrimination was assessed using classification plots and the area under the ROC curve. An optimum cut-off for the test variable, plus associated sensitivity and specificity achieved, were also determined. Further analyses were conducted on the same sample augmented with ERA patients, to assess the correlation between TREM, CRP and CCP titre values in this group; and on ERA patients only, to assess the correlation between TREM and DAS28 values in this group.  

Results: Duration of follow-up was 0 to 133 months, mean duration of 36 months (SD 31.2).  Mean time to RA diagnosis in those that progressed was 11.5 months (SD 14.3).   

Variable

Group

 
ERA ACPA+ Prog ACPA+ NProg All
Gender (n (%))       Female 9 (56.2%) 10 (62.5%) 11 (68.7%) 30 (62.5%)
Age (years) (mean (SD)) 55.2 (14.8) 53.8 (13.6) 53.9 (10.3) 54.3 (12.7)
TREM IU (mean (SD)) 539.3 (207.9) 711.0 (292.0) 405.0 (230.4)* 554.8 (271.9)
CRP ng/l (mean (SD)) 40.3 (61.0) 4.77 (5.61)* 4.53 (6.59)** 18.6 (41.6)
CCP IU (mean (SD)) 92.4 (127.1) 174.9 (108.8) 132.5 (135.1) 133.3 (126.1)
*n=15; **n=10        

A binary logistic regression model found that TREM was significantly associated with progression (p=0.009). The OR of 1.006 (95% CI 1.002 to 1.011) indicated that at best estimate, the odds of progression increased by 0.6% with each increase of 1 unit of TREM.  The model classified 80.6% of cases correctly, with 12 out of 16 (75.0%) of ACPA+ P cases and 13 out of 15 (86.7%) of ACPA+ NP cases correctly classified. The area under the ROC curve was 0.825 (95% CI 0.674 to 0.976).  Optimum combinations of sensitivity (81.3%) and specificity (80.0%) were obtained from a cut-off TREM value of 521.3 units.  There were no substantive correlations between TREM, CRP values and CCP values.

Conclusion: In this first assessment high level of sTREM is significantly associated with disease progression in at-risk individuals.  Furthermore, higher sTREM values are associated with greater odds of progression. It has potential to offer insights regarding disease pathogenesis and warrants further research.  References: 1. Bouchon A et al, Nature 2001  


Disclosure: L. Hunt, None; S. Musaad, None; J. Stephenson, None; B. Burn, None; I. Matsuura, None; K. Mankia, None; J. L. Nam, None; P. Emery, Pfizer,MSD,Abbvie,BMS,UCB,Roche,Novartis,Samsung, Sandoz, Eli Lillyand Company, 5.

To cite this abstract in AMA style:

Hunt L, Musaad S, Stephenson J, Burn B, Matsuura I, Mankia K, Nam JL, Emery P. Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/triggering-receptor-expressed-on-myeloid-cells-trem-as-a-novel-indicator-of-disease-progression-in-at-risk-individuals/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/triggering-receptor-expressed-on-myeloid-cells-trem-as-a-novel-indicator-of-disease-progression-in-at-risk-individuals/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology